Regular Article
Mechanisms of Lower Maintenance Dose of Tacrolimus in Obese Patients

https://doi.org/10.2133/dmpk.DMPK-13-RG-110Get rights and content

Summary:

A retrospective analysis suggested that blood tacrolimus concentrations were consistent among patients with a body mass index (BMI) that was lean (< 18.5), normal (≥ 18.5 and < 25) or overweight/obese (> 25). The average maintenance dose of tacrolimus in patients with BMI  25 was significantly lower compared with that in patients with a BMI of less than 25. Lean and obese Zucker rats fed a normal diet were given tacrolimus intravenously or orally. The blood concentrations of tacrolimus in obese rats were significantly higher than those in lean rats after administration via both routes. The moment analysis has suggested that CLtot and Vdss of tacrolimus were not significantly different between lean and obese rats. The bioavailability was higher in obese rats, compared with that in lean rats. The protein expression of Cyp3a2 in the liver was significantly decreased in obese rats, compared with lean rats, while P-gp in the small intestine was also significantly decreased in obese rats. These results suggested that the steady-state trough concentration of tacrolimus in obese patients was well maintained by a relatively low dose compared with that in normal and lean patients, presumably due to increased bioavailability.

References (47)

  • S. Pendyala et al.

    Diet- induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis

    Am. J. Clin. Nutr.

    (2011)
  • A. Nawa et al.

    Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions

    Life Sci.

    (2010)
  • A.M. Belliard et al.

    Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells

    J. Pharm. Sci.

    (2004)
  • World Health Organization

    Obesity and Overweight

  • M. Kotlyar et al.

    Effects ofobesity on the cytochrome P450 enzyme system

    Int. J. Clin. Pharmacol. Ther.

    (1999)
  • R. Jain et al.

    Implications of obesity for drug therapy: limitations and challenges

    Clin. Pharmacol. Ther.

    (2011)
  • R. Venkataramanan et al.

    Pharmacokinetics of FK 506: preclinical and clinical studies

    Transplant. Proc.

    (1990)
  • F.K. Japanese

    506 Study Group: Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration

    Transplant. Proc.

    (1991)
  • T. Shimada et al.

    Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy

    Transplantation

    (2002)
  • S. Masuda et al.

    Effect ofintestinal P-glycoprotein on daily Tacrolimus trough level in a living donor small bowel recipient

    Clin. Pharmacol. Ther.

    (2000)
  • T. Hashida et al.

    Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation

    Clin. Pharmacol. Ther.

    (2001)
  • P.Y. Cheng et al.

    Hepatic cytochrome P450 regulation in disease states

    Curr. Drug Metab.

    (2001)
  • K. Yoshinari et al.

    Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet

    Pharm. Res.

    (2006)
  • Cited by (20)

    View all citing articles on Scopus

    This work was supported in part by JSPS KAKENHI Grants No. 24790149 and No. 23590173.

    View full text